Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Aug 16;17(1):69.
doi: 10.1186/s13045-024-01594-x.

Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma

Allison Rosenthal  1 , Javier Munoz  2 , Monika Jun  3 , Tongsheng Wang  3 , Alex Mutebi  3 , Anthony Wang  4 , Shibing Yang  3 , Kojo Osei-Bonsu  4 , Brian Elliott  3 , Fernando Rivas Navarro  5 , Junhua Yu  4 , Samantha Brodkin  3 , Mariana Sacchi  3 , Andrew Ip  6   7
Affiliations
Comparative Study

Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma

Allison Rosenthal et al. J Hematol Oncol. .

Abstract

Many therapies are available for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after ≥ 2 lines of therapy, albeit with scant evidence on the comparative effectiveness of these therapies. This study used inverse probability of treatment weighting to indirectly compare treatment outcomes of epcoritamab from the EPCORE NHL-1 trial with individual patient data from clinical practice cohorts treated with chemoimmunotherapy (CIT) and novel therapies (polatuzumab-based regimens, tafasitamab-based regimens, and chimeric antigen receptor T-cell [CAR T] therapies) for third-line or later R/R large B-cell lymphoma (LBCL) and DLBCL. In this analysis, epcoritamab demonstrated significantly better response rates and overall survival rates than CIT, polatuzumab-based regimens, and tafasitamab-based regimens. No statistically significant differences in response rates or survival were found for epcoritamab compared with CAR T in R/R LBCL.

Keywords: Diffuse large B-cell lymphoma; Electronic health records; Mortality; Non-Hodgkin lymphoma; Propensity score weighting; Proportional-hazards models; Retrospective studies.

PubMed Disclaimer

Conflict of interest statement

Allison Rosenthal: Educational Workshop Speaker Role: RMEI, Curio Science, Targeted Oncology, OncLiveU. Javier Munoz: Consulting: Pharmacyclics/AbbVie, Bayer, Gilead/Kite, Pfizer, Janssen, Juno/Celgene, BMS, Kyowa, Alexion, Fosunkite, Innovent, Seattle Genetics, Debiopharm, Karyopharm, Genmab, ADC Therapeutics, Epizyme, BeiGene, Servier, Novartis, MorphoSys/Incyte, Secura Bio, TG Therapeutics, MEI, Lilly/Loxo; Research Funding: Bayer, Gilead/Kite, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, Millennium; Honoraria: Targeted Oncology, OncView, Curio, Kyowa, Physicians’ Education Resource, Seattle Genetics; Speakers Bureau: Gilead/Kite, Kyowa, Bayer, Pharmacyclics/Janssen, Seattle Genetics, Acrotech/Aurobindo, BeiGene, Verastem, AstraZeneca, Celgene/BMS, Genentech/Roche. Monika Jun, Tongsheng Wang, Alex Mutebi, Fernando Rivas Navarro, Samantha Brodkin, Mariana Sacchi: Genmab: Current Employment. Brian Elliott: Genmab: Current Employment and Stockholder. Shibing Yang: Genmab: Former Employment. Anthony Wang, Kojo Osei-Bonsu, Junhua Yu: AbbVie: Current Employment. Andrew Ip: Honoraria: Pfizer; Speakers Bureau: Seagen; Advisory Board: Secura Bio, AstraZeneca, TG Therapeutics.

Figures

Fig. 1
Fig. 1
Hazard ratios for OS outcomes. Epcoritamab vs A CIT (LBCL); B CAR T (LBCL); C Pola (DLBCL); and D Tafa (DLBCL). CAR T, chimeric antigen receptor T-cell; CI, confidence interval; CIT, chemoimmunotherapy; DLBCL, diffuse large B-cell lymphoma; Epco, epcoritamab; HR, hazard ratio; LBCL, large B-cell lymphoma; NE, not estimable; NR, not reached; OS, overall survival; Pola, polatuzumab; Tafa, tafasitamab
See this image and copyright information in PMC

References

    1. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38:155–65. 10.1200/JCO.19.00172 - DOI - PMC - PubMed
    1. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800–8. 10.1182/blood-2017-03-769620 - DOI - PMC - PubMed
    1. Wang L, Li LR, Young KH. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol. 2020;13:175. 10.1186/s13045-020-01011-z - DOI - PMC - PubMed
    1. Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2023;41:2238–47. 10.1200/JCO.22.01725 - DOI - PMC - PubMed
    1. FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma [press release]. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accele.... Accessed 10 July 2023.

MeSH terms

Substances

LinkOut - more resources